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1031-199 Rapamycin Inhibits Expression of Minichromosome 
Maintenance Proteins in Vascular Smooth Muscle Cells 
Dennis Bruemmer, Fen Yin, Joey Liu, Eckart Fleck, Andre van Herie, Ronald Law, 
University of California, Los Angeles, CA, German Heart Institute, Berlin, Germany 
Background: Rapamycin inhibits proliferation of vascular smooth muscle cells (VSMC) 
and local delivery of rapamycin from polymer-coated stents represents a novel therapeu- 
tic strategy for preventing postangioplasty restonsis. The molecular mechanims by which 
rapamycin exerts its antiproliferative activity involves an inhibition of Gi +S phase transi- 
tion. However, the effects of rapamycin on S phase and DNA replication remain to be 
investigated. In the present study the effect of rapamycin on minichromosome mainte- 
nance (MCM) proteins 6 and 7, two proteins essential for initiation of DNA’replication. 
was investigated in rat aortic VSMC. 
Methods and results: Rapamycin substantially inhibited mitogen-induced MCM6 and 
MCM7 mRNA (68.2 f 5.6 %. 71.2 f 6.9 % inhibition vs. IO % FBS after 12 hours treat- 
ment with 100 nM rapamycin, n=3, ~~0.05) and protein (61 .l * 8.3 %. 52.7 f 6.0 % inhi- 
bition vs. 10 % FBS after 24 hours treatment with 100 nM rapamycin, n=3, ~~0.05) 
expression in a dose-dependent fashion. Transient transfection experiments revealed 
that rapamycin inhibited MCM6 and MCM7 promotor activity (58.3 f 6.8 %, 67.1 f 8.4 % 
inhibition vs. 10% FBS after 48 hours treatment with 100 nM rapamycin, n=3, ~~0.05) 
implicating a transcriptional mechanism. MCM6 and MCM7 transcriptional activation is 
regulated by E2F and activity of a luciferase reporter plasmid driven by four E2F ele- 
ments was also strongly inhibited by rapamycin (63.1 f 7.3 % inhibition after 48 hours, 
n=3. p<O.O5). The inhibitory effect of rapamycin on MCM8 and MCM7 was reversed by 
adenoviral mediated overexpression of E2F, indicating that their downregulation by rapa- 
mycin involves an E2F-dependent mechanism. 
Conclusion: These observation suggest that rapamycin inhibits MCMG and MCM7 
expression by blocking EZF function which may contribute importantly to the inhibition of 
VSMC DNA synthesis by rapamycin. 
1031-200 Site Specific Systemic Delfvery of Rapamycin With 
Perfluorobutane Gas Microbubble Carrier Reduced 
Neointimal Formation in the Porcine Coronary 
Restenosis Model 
Nicholas N. Kipshidze, Ahmadian Yazdi. Fermin Tio, Rufus Seaborn, Tom Porter, Milena 
G. Adamian. Fena Xie. Georae Danaas. Martin B. Leon. Jeffrev W. Moses. Patrick 
Iversen, Lenox Hill Heart and Vascular Institute, Cardiovascular Research Foundation, 
New York, NY, Cardiovascular Research Institute, Washington, DC 
Hypothesis: Stent based delivery of Rapamycin was shown to inhibit intimal hyperplasia 
in animal models and to eliminate restenosis in clinical trials. However the potential for 
long-term adverse effects secondary to the polymeric coatings has been subject of con- 
cern. It was previously demonstrated that perfluorobutane gas panicles adhere to injured 
arteries. Additionally perfluorobutane gas enhances cell entry for drugs on the surface of 
bubbles that come into contact with denuded vessel surfaces. The purpose of this study 
was to investigate the effects of PGMC-based delivery of Rapamycin on expression of 
p21 and p27 in vascular tissue and restenosis in porcine arteries after stent implantation. 
Methods: Seven pigs underwent stent implantation (3 stentslanimal). Four pigs received 
IV injection of PGMC and 2mg of Rapamycin. Two served as control. Four hours later, 3 
pigs were sacrificed and stented segments were analyzed by HPLC and western blot. In 
chronic experiments, 4 pigs (12 stent sites) were sacrificed at 28 days. 
Results: HPLC analysis of plasma samples of treated animals showed mmimal pres- 
ence of Rapamycin, whereas HPLC of the treated arteries demonstrated high concentra- 
tion of the drug (190-280 mcg). Western blot analysis of the stented vessels 
demonstrated over-expression of p21 and ~27. Morphometry showed that the neointimal 
was significantly reduced 40% in the Rapamyciwbubble group compared with control 
(2.84 eO.84 vs. 4.77 *I .71 mm2 respectively, peO.05). Conclusion: In this animal model 
site-specific systemic delivery of Rapamycin using PGMC resulted in over-expression of 
p-21 and p-27 in the stented segments and significantly inhibited neointimal formation. 
1031-201 Local Delivery of lrinotecan With Drug-Eluting Stents 
Inhibits Neointimal Proliferation In 
Hypercholesterolemic Rabbits 
Daniel H. Bermcal, German E. Gonzalez, Celina Morales, Mauricio G. Cohen, Ricardo J. 
Gelpi, Liliana R. Grinfeld, Hospital Italian0 de Buenos Aires, Buenos Aires, Argentina 
Background: Recent studies have shown that local delivery of cytostatic or antineoplas- 
tic drugs inhibits neointimal growth after stent implantation. lrinotecan inhibits DNA repli- 
cation. 
Objective: To assess the effect of irinotecan-eluting stents on neointimal growth in the 
aorta of hypercholesterolemic rabbits. 
Methods: Phosphorylcholine (PC) coated stents were deployed in the aorta of 30 hyper- 
cholesterolemic New Zealand rabbits. All stents had a diameter of 3.0mm and a length of 
15mm. Group 1 (n=lO), the control group, received bare stents, group 2 (n=lO) received 
a PC-coated stent with low-dose idnotecan (46.5~) and group 3 (n=lO) received a PC- 
coated stent with high-dose irinotecan (129mg). All rabbits were sacrificed by the sec- 
ond month after stent-implantation. Morphometric analysis was performed to assess 
neointimal growth thickness (NT). A semi-quantitative injury score (from 0 to 3) was used 
to analyze necrosis (N), macrophages (M), edema (E), hemorrhage (H), and fibrin con- 
tent(F). in the stented segments. 
Resutts: In 3 cases the procedure was unsuccessful and 4 rabbits died before complet- 
ing the e-month follow-up period. These cases were excluded. No differences were 
observed in terms of injury score. The following table displays the study results.( ‘PC 
0.05 vs Group 1). 
NT NM EHF 
Group1 (n=7) 207.9+31.6 0 1.14r0.15 0 0 0.50r0.20 
GroupP(n.7) 156.3k36.5 0 0.75r0.29 0 0 0.75kO.29 
Group3 (n=9) 113.4+17.2’ 0 1.29+0.20 0 0 1.00~0.00’ 
Conclusions: PC-coated stems loaded with high-dose innotecan inhibit neointimal thick- 
ening III the abdominal aorta of hypercholesterolemic rabbits. This effect was not accom- 
panted by cellular injury. 
1031-202 Active Glycogen Synthase Kinase-3 Gene Transfer 
Inhibits Smooth Muscle Proliferation and Neointima 
Formation After Balloon Injury in Rats 
Kvuna-Woo Park, Han-MO Yang, In-Ho Chae, Hyo-Soo Kim, Kenneth Walsh, Clinical 
Research Center, Seoul National University Hospital, Seoul, South Korea, Whitaker 
Cardiovascular Institute, Boston University School of Medicine, Boston, MA 
Background: Glycogen Synthase Kinase(GSK)-3 is a crucial factor in many cellular sig- 
nailing pathways and plays an important role in protein synthesis, cell proliferation, differ- 
entiation, microtubule dynamics. cell motility, and survival. We recently reported the 
antiproliferative and antimigratory effects of active GSK-Z@ gene transfer in human aortic 
smooth muscle cells in vitro. 
Methods: To investigate the effect of active GSK-38 gene transfer on the formation of 
neointima after balloon injury in rats in viva we delivered adenoviral vectors expressing 
the constitutively active form of GSK-B3 (GSK-SSA: 9rh serine switched to alanine) or a 
control gene into rat carotid arterial segments after balloon injury with a 2F Forgarty cath- 
eter. Viral infusion mixtures containing dxlO$fu of virus diluted to a total volume of 
1 OOuL were incubated in the arterial lumen for 20minutes and the effects of gene delivery 
were evaluated 3 days and 2 weeks after gene delivery with morphometry and immuno- 
histochemical staining. 
Results: There were no significant differences in intimal, medial, and lumen areas at 3 
days after the procedure. However, two weeks after gene delivery, the active GSK-38 
gene transfer resulted in a significantly lower intimafmedia (I/M) ratio (0.29kO.06 vs 
0.86t0.09, pcO.01) and a greater lumen area (0.41+0.02 vs 0.31~0.01mm’, ~~0.01) 
compared to the control gene transfected group. This was due to a significant reduction 
in intimal area (0.05*0.01 vs 0.15+0.02mmz, p<O.Ol) while the medial area was similar 
(0.17+0.01 vs 0.18iO.01 mm’, p=O.21). Proliferating cell nuclear antigen (PCNA) positive 
cells were significantly reduced in the neointima at 14 days in the active GSK-33 gene 
transferred group (2.97r0.29 vs 5.71+0.50%, p<O.Ol). 
Conclusion: In viva delivery of the active GSK-8l gene inhibits smooth muscle prolifera- 
tion and neointima formation after balloon injury in rats, and may be a future target for 
gene therapy to inhibit restenosrs after balloon angioplasty. 
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1051-187 The Smoker’s Paradox in Patients Undergoing 
Percutaneous Coronary Intervention: A Report From 
the Dynamic Registry 
Daniel Wachsman, Faith Seizer, Katherine M. Detre, David 0. Williams, Alice K. Jacobs, 
Boston Medical Center, Boston, MA, University of Pittsburgh, Pittsburgh, PA 
Background: Despite the known detrimental effects of smoking on the incidence of and 
mortality from CAD, a paradoxical beneficial effect has been observed in smokers with 
myocardial infarction (Ml). Methods: To determine whether the smoker’s paradox exists 
for patients undergoing percutaneous coronary intervention (PCIJ. we evaluated 4,389 
patients in the 1997-99 NHLBI Dynamic Registries, of whom 1,138 were current (CSM). 
1,762 former (FSM) and 1,469 never (NSM) smokers. All comparisons were made to the 
NSM group. Results: CSM and FSM patients were significantly (all pcO.001) younger 
(55.9 vs 64.4 vs 65.7 yrs) and less often female (31.7 vs 26.3 vs 50.0%) in comparison to 
NSM. Among CSM, the prevalence of diabetes (20.2 vs 33.7%) hypertension (53.7 vs 
66.0%) CHF (5.6 vs 11.3%). prior PCI (20.5 v’s 29.1%). and prior CABG (7.6 vs 17.4%) 
was lower whereas the prevalence of pulmonary disease (10.3 vs 4.0%) and presenta- 
tion with an Ml (33.5 vs 20.5%) was higher compared to NSM (all p<O.OOl). Angiographic 
differences also existed, with CSM significantly (all p<O.OOl) more likely to present with 
single-vessel disease (47.9 vs 42.2%) lesion location in the right coronary artery (36.7 v’s 
30.5%) and to have vessels that were more thrombotic (24.7 vs 18.3%), ulcerated (13.9 
vs 10.5%). occluded (17.3 vs 11.8%) and collateralized (16.0 vs 12.4%) in COmparisOn 
to NSM. Despite similar procedural success rates, in-hospital mortality was significantly 
lower in CSM and FSM (0.8 and 1 .O vs 2.0%, both p&05) than in NSM. However, after 
adjustment for baseline differences, the risk of mortality did not differ from NSM (CSM vs 
NSM Odds Ratio 0.58, 95% Cl 0.24, 1.39 and FSM vs NSM Odds Ratio 0.61, 95% Cl 
0.31, 1.19). At one year, mortality (3.7 vs 5.7%) and repeat revascularization (18.5 vs 
20.6%) rates were significantly (~~0.05) lower in CSM compared to NSM patients but 
again, after adjustment, the relative risk of death, Ml or repeat revasculanzation was sim- 
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ilar between the groups. 
Conclusion: These data suggest that in patients undergoing PCI, the smoker’s paradox is 
an artifact that can be accounted for by younger age and less severe underlying disease 
among smokers rather than a true benefit of smoking. 
1051-188 Distal Myocardial Protection With lntracoronary 
Propranolol During Percutaneous Coronary 
Intervention Is Widely Applicable 
Fen Wei Wang, Abdulfath Osman, Javier Otero, George A. Stouffer, Sergio Waxman, 
Adnan Afzal, Angelo Anzuini. Barrv F. Uretsky, The University of Texas Medical Branch, 
Galveston, TX 
Background: Myocardial necrosis (Ml) after percutaneous coronary intervention (PCI) IS 
associated with an increased incidence of late adverse outcomes. Methods: We con- 
ducted a prospective randomized. placebo-controlled trial in 150 PCI patients to deter- 
mine whether intracoronary (IC) propranolol ( 0.015mglkg) decreases post - PCI MI and 
in which subgroups this effect occurs. Results: Post -PCI Ml &K-MB > upper limit of nor- 
mal) developed in 17% of IC propranolol pts (13/75) and 36% of placebo pts ( 27175) 
(p=O.Ol). The figure shows that this effect is widely applicable including the subgroup 
receiving prophylactic GP llbillla inhibitors (28% of pts) and chronic oral pre-PCI beta- 
blockers (64%). Factors associated with decreased risk of MI were IC propranolol (OR: 
0.40, Cl: 0.17-0.91, p= 0.03) and prophylactic GP Ilb/llla use (OR: 0.41, Cl: 0.14-I .08, p= 
0.08). IC propranolol decreased MIS in GP llblllla pts ( O%vs. 41%) and pts on chronic 
beta blockers ( 16% vs. 35%).Factors associated with increased Ml were age > 60 years 
old and mechanical complications during PCI. IC propranolol decreased MI risk in older 
pts (19% vs. 46%) and in patients with mechanical complications (41% vs. 61%). Con- 
clusion: These data are consistent with IC propranolol being a broadly effective cardio- 
protective agent during PCI. 
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1051-189 Reduction of Restenosis in Percutaneous Coronary 
Interventions by Hyperbaric Oxygen Therapy 
Mohsen Sharifr Wassim Fares, lsam Abdel-Karim, Dan Petrea, Michael Koch, Dale S. 
Adler, Vincent J. Pompili, Joseph Sopko, St. Vincent Charity Hospital, Cleveland, OH, 
Case Western Reserve University, Cleveland, OH 
Background: Hyperbaric Oxygen Therapy (HOT)is a potent modality in the management 
of slow healing wounds.Percutaneous Coronary Interventions(PCl)uniformly create min. 
iature wounds by the disruptive effects of the interventional hardware,thereby triggering 
the humoro-cellular responses leading to restenosis.lt is intriguing to postulate that early 
healing of these miniature wounds by HOT may decrease restenosis.The following con- 
stitutes our interim comparative flndings. 
Methods: Of 68 patients Initially enrolled,28 were randomized to the HOT arm and 40 to 
the control group.The patients underwent PCI for unstable angina or acute myocrdial inf- 
arction(Ml) .All patients received at least one stent.Patients in the HOT arm underwent 2 
hyperbaric dives using the Sechrist 25008 MonoplaceSystem(Sechrist Inds., Anna- 
heim,CA):one dive 2 hours before or immediately after PCl,and the other withtn 18 hours 
of the first dive.Each dive consisted of 100% Oxygen at 2 bars for 90 minutes. 
Results: The primary endpoints consisted of major adverse cardiac events at 8 
months(Table).Repeat coronary angiography was performed for chest pain or Ml in 3 
patients of the HOT arm and 8 of the control group.Anglographlc restenosis in the target 
lesion was found in 7of the control and 0 of the HOT arm(p=0.007). 
Conclusions: HOT is a safe and effective adjunct to PCI and IS associated with a signdi- 
cant reduction I” the restenosls rate.Furthermore,it substantially reduces recurrence of 
late angina1 symptoms. 
Adverse Events at 8 Months 
HOT Control p Value 
No=28 No=40 
Composite Endpoints:Death, MI,CABG,TLR 1 IO p=O.O23 
Death 0 2 NS 
Ml 1 5 NS 
CABG 0 0 NS 
TLR 0 6 ~~0.036 
Recurrent Angina 0 8 p=o.o14 
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1051-190 Preprocedure Inflammatory State Predicts 
Periprocedural Myocardial Infarction After Elective 
Percutaneous Coronary intervention: An EPIC 
Substudy 
Herbert D. Aronow, Martin J. Quinn, Hitinder S. Gurm, Michael S. Lauer, DamelIe M. 
Brennan. Eric J. Topol, A. Michael Lincoff, The Cleveland Clinic Foundation, Cleveland, 
OH 
Background: Preliminary data suggest that systemic inflammation may influence the 
clinical course following percutaneous coronary intervention (PCI). The relationship 
between inflammation at baseline and periprocedural myocardial infarction (Ml) has not 
been well explored. Methods: We examined the effect of systemic inflammation at base- 
tine (white blood cell count [WBC]) on the incidence of Ml (CKMB > 3x upper limit of nor- 
mal) after elective PCI among high-risk patients without recent acute coronary 
syndromes from the EPIC study (n=880). Results: Overall, Ml occurred in 146 (16.6%). 
The incidence of Ml in the 1”: Znd and 3” WBC tertiles was 6.5, 9.6 and 13.8%, respec- 
tively (p for trend O.OOlMS) [Figure]. In a multivariable logistic regression model, increas- 
ing WBC count (OR for each lOOO/uL increase 1.136 [95% Cl 1.049-1.231]. p=O.O02) 
was independently associated with a higher risk of peri-procedural Ml. Conclusion: Pre 
procedure inflammatory state predisposes patients to peri-procedural Ml. A randomized 
trial comparing immediate PCI versus PCI deferred for anti-inflammatory pre-treatment 
(e.g., statins) appears warranted. 
1051-191 Alpha-Blockade in Patients With Coronary Artery 
Disease: Implications for Fractional Flow Reserve 
Measurements 
Emanuele Barbato, Wilbert Aarnoudse, Jozef Bartunek. S&fan Carlier, Marc 
Vanderheyden, William Wijns. Guy R. Heyndrickx,Nico H. Pills, Bernard De Bruyne, 
Cardiovascular Center OLVZ, Aalst, Belgium, Catharina Hospital, Eindhoven, The 
Netherlands 
Adenosine (ADO), used for diagnostic purposes, is supposed to exhaust myocardial 
resistance (MR). In patients (pts) with coronary artery disease, alpha vasomotor tone is 
enhanced and ADO might fail to reach minimal MR. 
To determine the presence of clinically relevant residual MR after ADO administration. 
Fractional flow reserve (FFR=hyperemic Pd/Pa, where Pa is mean aortic pressure and 
Pd mean distal coronary pressure) was assessed in. a) Gr I, 13 coronary s&noses 
(51*12 %, Diameter Stenosis) of 13 pts. during IC bolus of ADO, before and 3 min after 
IC bolus of phentolamine (PHE, 1 mg), an alpha I-. alpha 2-adrenergic blacker, b) Gr 2, 
12 stenoses (48~11 %, DS) of 12 pts. during IV infusion of ADO, and during IV ADO plus 
PHE (PHE 1 mg, given on top of maximal ADO hyperemia); c) Gr 3, 8 stenoses of 8 pts 
(44r5 %. DS), during IV ADO, and during IV ADO plus high dose PHE (PHE 3 mg); d) Gr 
4, 13 stenoses (5Oi13 %, DS) of 13 pts, during IC ADO, before and 3 min after IC bolus 
of urapidil (URA, IO mg). an alpha I-adrenergic blocker; e) Gr 5, 13 stenoses (5OklO %, 
DS) of 13 pts, during IV ADO, and during IV ADO plus URA. All pts received IC isosor- 
bide dinitrate (ISDN, 3 mg) at the beginning of the protocols. All pts had normal left ven- 
tricular function. 
Since epicardial stenosis remained unchanged (MLD before vs. after, Gr 1: 1,25~0,42 vs. 
1,33+0,39, “s; Gr2: 1,48~0,22”s. 1,44*0,38, “s; Gr3: 1,47+O,lOvs. 1,53*0,16, ns; Gr 
4: 1,52*0,15 vs 1,44*0,15, ns; Gr 5: 1,41*0,13 vs. 1,36iO,lO. ns), changes in PdiPa 
ratio reflect changes in MR. With IC ADO, Pd/Pa ratio did not change before and after 
PHE (0.79iO.04 vs. 0.79+0.04, ns). A slight decrease in Pd/Pa ratio was observed after 
URA (0.78*0.03 vs. 0.76+0.03, ~~0.05). During IV ADO, Pd/Pa ratio remained constant 
before and after PHE (0.79iO.03 vs. 0.77*0.03. ns) and even at h!gh dose PHE 
(0.78r0.04 vs. 0.76r0.05, ns). A small decrease was observed after URA (0.77*0.03 vs. 
0.74iO.03, ~~0.05). Neverthless, only 4 pts had a significant decrease I” PdiPa ratio. 
PHE and URA administratlon induced only transient changes in heart rate and in blood 
pressure. 
In the diagnostic setting, when given on top of ADO, URA (but not PHE) induces a limited 
further decrease in MR. Yet this changed the clinical decision in only 7 % of pts. 
